| __timestamp | MannKind Corporation | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 100244000 | 14182353 |
| Thursday, January 1, 2015 | 29674000 | 15503028 |
| Friday, January 1, 2016 | 14917000 | 16183585 |
| Sunday, January 1, 2017 | 14118000 | 22382849 |
| Monday, January 1, 2018 | 8737000 | 33038206 |
| Tuesday, January 1, 2019 | 6900000 | 31777040 |
| Wednesday, January 1, 2020 | 6248000 | 41464134 |
| Friday, January 1, 2021 | 12312000 | 67178053 |
| Saturday, January 1, 2022 | 19721000 | 52531000 |
| Sunday, January 1, 2023 | 31283000 | 68914000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, research and development (R&D) is the lifeblood of innovation. Over the past decade, MannKind Corporation and Pharming Group N.V. have demonstrated contrasting strategies in their R&D investments. MannKind's R&D expenses peaked in 2014, with a significant 41% of their total expenditure over the decade, before experiencing a sharp decline. By 2020, their spending had decreased by nearly 94%, reflecting a strategic shift or financial constraints.
Conversely, Pharming Group N.V. has shown a steady increase in R&D allocation, with a notable 386% rise from 2014 to 2023. This upward trend underscores their commitment to innovation and growth. By 2023, Pharming's R&D spending was nearly double that of MannKind, highlighting their aggressive pursuit of new therapeutic solutions. These trends offer a glimpse into the strategic priorities of these companies and their potential impact on future pharmaceutical advancements.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and MannKind Corporation
R&D Insights: How Alnylam Pharmaceuticals, Inc. and MannKind Corporation Allocate Funds
BeiGene, Ltd. vs Pharming Group N.V.: Strategic Focus on R&D Spending
Incyte Corporation or Pharming Group N.V.: Who Invests More in Innovation?
Jazz Pharmaceuticals plc vs MannKind Corporation: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Pharming Group N.V.
Pharming Group N.V. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Pharming Group N.V. vs Amneal Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Pharming Group N.V. and Ligand Pharmaceuticals Incorporated
Research and Development Expenses Breakdown: Viking Therapeutics, Inc. vs MannKind Corporation
R&D Insights: How PTC Therapeutics, Inc. and MannKind Corporation Allocate Funds
Research and Development Expenses Breakdown: Veracyte, Inc. vs MannKind Corporation